BioVersys AG (CHIX:BIOVZ) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 06, 2026)


CHIX:BIOVZ BioVersys AG CHIX:BIOVZ
14 GF Score
Price CHF27.10
View Full Analysis

What is BioVersys AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioVersys AG's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CHIX:BIOVZ vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, BioVersys AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where BioVersys AG's Margin of Safety % (DCF FCF Based) falls into.


CHIX:BIOVZ
14GF Score
BioVersys AG CHIX:BIOVZ
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Business Description

Other Exchanges W33:GermanyBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score

Get the complete analysis for CHIX:BIOVZ

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.10
Price